These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36446653)

  • 1. Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - an ACCESS cohort study.
    Willame C; Dodd C; Durán CE; Elbers R; Gini R; Bartolini C; Paoletti O; Wang L; Ehrenstein V; Kahlert J; Haug U; Schink T; Diez-Domingo J; Mira-Iglesias A; Carreras JJ; Vergara-Hernández C; Giaquinto C; Barbieri E; Stona L; Huerta C; Martín-Pérez M; García-Poza P; de Burgos A; Martínez-González M; Bryant V; Villalobos F; Pallejà-Millán M; Aragón M; Carreras JJ; Souverein P; Thurin NH; Weibel D; Klungel OH; Sturkenboom M
    Vaccine; 2023 Jan; 41(1):251-262. PubMed ID: 36446653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study.
    Li X; Ostropolets A; Makadia R; Shoaibi A; Rao G; Sena AG; Martinez-Hernandez E; Delmestri A; Verhamme K; Rijnbeek PR; Duarte-Salles T; Suchard MA; Ryan PB; Hripcsak G; Prieto-Alhambra D
    BMJ; 2021 Jun; 373():n1435. PubMed ID: 35727911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Background rates of adverse events of special interest for COVID-19 vaccines: A multinational Global Vaccine Data Network (GVDN) analysis.
    Phillips A; Jiang Y; Walsh D; Andrews N; Artama M; Clothier H; Cullen L; Deng L; Escolano S; Gentile A; Gidding G; Giglio N; Junker T; Huang W; Janjua N; Kwong J; Li J; Nasreen S; Naus M; Naveed Z; Pillsbury A; Stowe J; Vo T; Buttery J; Petousis-Harris H; Black S; Hviid A
    Vaccine; 2023 Oct; 41(42):6227-6238. PubMed ID: 37673715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines.
    Pillsbury A; Phillips A; Deng L; Quinn H; Macartney K; Gidding H
    Vaccine; 2023 May; 41(22):3422-3428. PubMed ID: 37088604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US.
    Li X; Burn E; Duarte-Salles T; Yin C; Reich C; Delmestri A; Verhamme K; Rijnbeek P; Suchard MA; Li K; Mosseveld M; John LH; Mayer MA; Ramirez-Anguita JM; Cohet C; Strauss V; Prieto-Alhambra D
    BMJ; 2022 Oct; 379():e071594. PubMed ID: 36288813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals.
    Faksova K; Walsh D; Jiang Y; Griffin J; Phillips A; Gentile A; Kwong JC; Macartney K; Naus M; Grange Z; Escolano S; Sepulveda G; Shetty A; Pillsbury A; Sullivan C; Naveed Z; Janjua NZ; Giglio N; Perälä J; Nasreen S; Gidding H; Hovi P; Vo T; Cui F; Deng L; Cullen L; Artama M; Lu H; Clothier HJ; Batty K; Paynter J; Petousis-Harris H; Buttery J; Black S; Hviid A
    Vaccine; 2024 Apr; 42(9):2200-2211. PubMed ID: 38350768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
    Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
    PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterizing the incidence of adverse events of special interest for COVID-19 vaccines across eight countries: a multinational network cohort study.
    Li X; Ostropolets A; Makadia R; Shaoibi A; Rao G; Sena AG; Martinez-Hernandez E; Delmestri A; Verhamme K; Rijnbeek PR; Duarte-Salles T; Suchard M; Ryan P; Hripcsak G; Prieto-Alhambra D
    medRxiv; 2021 Apr; ():. PubMed ID: 33791732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales.
    Kerr S; Joy M; Torabi F; Bedston S; Akbari A; Agrawal U; Beggs J; Bradley D; Chuter A; Docherty AB; Ford D; Hobbs R; Katikireddi SV; Lowthian E; de Lusignan S; Lyons R; Marple J; McCowan C; McGagh D; McMenamin J; Moore E; Murray JK; Owen RK; Pan J; Ritchie L; Shah SA; Shi T; Stock S; Tsang RSM; Vasileiou E; Woolhouse M; Simpson CR; Robertson C; Sheikh A
    PLoS Med; 2022 Feb; 19(2):e1003927. PubMed ID: 35192598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cohort Event Monitoring of Adverse Reactions to COVID-19 Vaccines in Seven European Countries: Pooled Results on First Dose.
    Raethke M; van Hunsel F; Thurin NH; Dureau-Pournin C; Mentzer D; Kovačić B; Mirošević Skvrce N; De Clercq E; Sabbe M; Trifirò G; Luxi N; Giovanazzi A; Shakir S; Klungel OH; Schmikli S; Sturkenboom M
    Drug Saf; 2023 Apr; 46(4):391-404. PubMed ID: 37024736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contextualising adverse events of special interest to characterise the baseline incidence rates in 24 million patients with COVID-19 across 26 databases: a multinational retrospective cohort study.
    Voss EA; Shoaibi A; Yin Hui Lai L; Blacketer C; Alshammari T; Makadia R; Haynes K; Sena AG; Rao G; van Sandijk S; Fraboulet C; Boyer L; Le Carrour T; Horban S; Morales DR; Martínez Roldán J; Ramírez-Anguita JM; Mayer MA; de Wilde M; John LH; Duarte-Salles T; Roel E; Pistillo A; Kolde R; Maljković F; Denaxas S; Papez V; Kahn MG; Natarajan K; Reich C; Secora A; Minty EP; Shah NH; Posada JD; Garcia Morales MT; Bosca D; Cadenas Juanino H; Diaz Holgado A; Pedrera Jiménez M; Serrano Balazote P; García Barrio N; Şen S; Üresin AY; Erdogan B; Belmans L; Byttebier G; Malbrain MLNG; Dedman DJ; Cuccu Z; Vashisht R; Butte AJ; Patel A; Dahm L; Han C; Bu F; Arshad F; Ostropolets A; Nyberg F; Hripcsak G; Suchard MA; Prieto-Alhambra D; Rijnbeek PR; Schuemie MJ; Ryan PB
    EClinicalMedicine; 2023 Apr; 58():101932. PubMed ID: 37034358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020.
    Moll K; Lufkin B; Fingar KR; Ke Zhou C; Tworkoski E; Shi C; Hobbi S; Hu M; Sheng M; McCarty J; Shangguan S; Burrell T; Chillarige Y; Beers J; Saunders-Hastings P; Muthuri S; Edwards K; Black S; Kelman J; Reich C; Amend KL; Djibo DA; Beachler D; Ogilvie RP; Secora A; McMahill-Walraven CN; Seeger JD; Lloyd P; Thompson D; Dimova R; MaCurdy T; Obidi J; Anderson S; Forshee R; Wong HL; Shoaibi A
    Vaccine; 2023 Jan; 41(2):333-353. PubMed ID: 36404170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England.
    Whiteley WN; Ip S; Cooper JA; Bolton T; Keene S; Walker V; Denholm R; Akbari A; Omigie E; Hollings S; Di Angelantonio E; Denaxas S; Wood A; Sterne JAC; Sudlow C;
    PLoS Med; 2022 Feb; 19(2):e1003926. PubMed ID: 35192597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study.
    Pottegård A; Lund LC; Karlstad Ø; Dahl J; Andersen M; Hallas J; Lidegaard Ø; Tapia G; Gulseth HL; Ruiz PL; Watle SV; Mikkelsen AP; Pedersen L; Sørensen HT; Thomsen RW; Hviid A
    BMJ; 2021 May; 373():n1114. PubMed ID: 33952445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 vaccine safety in Scotland - background rates of adverse events of special interest.
    Cullen LA; Grange Z; Antal K; Waugh L; Alsina MS; Gibbons CL; MacDonald LE; Robertson C; Cameron JC; Stockton D; O'Leary MC
    Public Health; 2023 Nov; 224():1-7. PubMed ID: 37688806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Safety Analysis of the ChAdOx1-nCoV-19 Corona Virus Vaccine: Results from a Prospective Observational Study in Priority Vaccinated Groups in North India.
    Kaur U; Fatima Z; Maheshwari K; Sahni V; Dehade A; Kl A; Yadav AK; Kansal S; Jaisawal V; Chakrabarti SS
    Drug Saf; 2023 Jun; 46(6):553-563. PubMed ID: 37133805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of AZD1222 and BNT162b2 COVID-19 Vaccination With Thromboembolic and Thrombocytopenic Events in Frontline Personnel : A Retrospective Cohort Study.
    Hviid A; Hansen JV; Thiesson EM; Wohlfahrt J
    Ann Intern Med; 2022 Apr; 175(4):541-546. PubMed ID: 35103482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study.
    Kang W; Shami JJP; Yan VKC; Ye X; Blais JE; Li X; Lee VHF; Chui CSL; Lai FTT; Wan EYF; Wong CKH; Wong ICK; Chan EW
    J Hematol Oncol; 2022 May; 15(1):66. PubMed ID: 35590336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety Monitoring of COVID-19 Vaccines: Perspective from the European Medicines Agency.
    Durand J; Dogné JM; Cohet C; Browne K; Gordillo-Marañón M; Piccolo L; Zaccaria C; Genov G
    Clin Pharmacol Ther; 2023 Jun; 113(6):1223-1234. PubMed ID: 36524423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.